Supplementary Text, Figures and Tables from Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies
Year: 2023
Type: supplementary-materials
Abstract: This file contains Supplementary Text, Supplementary Figures S1-S13 and Supplementary Tables S1, S3-S5, S9-S10, S14-S15, S18-S19. Supplementary Fig. S1. Validation of prognostic associations and biological properties of the CMS groups in primary CRCs Supplementary Fig. S2. The original CMS classifier fails to accurately identify the CMS groups in CRC cell lines Supplementary Fig. S3. Principal components analysis of cell lines based on gene expression Supplementary Fig. S4. Assessment of misclassification risk of CRC cell lines Supplementary Fig. S5. Additional template gene filter for classifier genes expressed in the tumor stroma Supplementary Fig. S6. Biological characteristics of the CMS groups are recapitulated in PDX models of CRC Supplementary Fig. S7. CRC cell lines analyzed by drug screening are representative with respect to gene expression and CMS groups Supplementary Fig. S8. Principal components analysis of in vitro drug screen data Supplementary Fig. S9. Validation of strong relative activity of EGFR inhibition in CMS2 Supplementary Fig. S10. Drug response analyses between CMS1/4 and CMS2/3 cell lines Supplementary Fig. S11. In vitro validation of strong relative sensitivity to HSP90 inhibition in CMS1 and CMS4 cell lines in published data Supplementary Fig. S12. Up-regulation of heat shock response in cell lines treated with luminespib Supplementary Fig. S13. Poor response to fluoropyrimidines in CMS4 cell lines Supplementary Table S1. Clinicopathological and molecular characteristics of consecutive patient series (n = 409) Supplementary Table S3. Enrichment of molecular characteristics among CMS groups in primary CRC Supplementary Table S4. Enrichment of clinicopathological characteristics among CMS groups in primary CRC Supplementary Table S5. Multivariable survival analyses Supplementary Table S9. Classification concordance between the original and new cancer cell-adapted CMS classifier in CRC cell lines Supplementary Table S10. Enrichment of molecular characteristics among CMS groups of CRC cell lines Supplementary Table S14. Overview of the molecular target classes for the highthroughput drug screening library Supplementary Table S15. Drugs with strong effect in MSI+ versus MSS cell lines Supplementary Table S18. Drugs with strong relative activity in CMS2 Supplementary Table S19. Differential gene expression in response to luminespib treatment
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4361923246